Pluristem Therapeutics CEO Issues Shareholder Update
November 12, 2019 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare
November 04, 2019 07:00 ET
|
Pluristem Therapeutics, Inc.
RESTORE Consortium, of which Pluristem is a leading member, is competing for up to a €1 billion award by the European CommissionWinner announcement is expected in May 2020 HAIFA, Israel, Nov. ...
Pluristem Therapeutics Recaps Key Opinion Leader Call Reviewing Hematological Programs
September 16, 2019 12:20 ET
|
Pluristem Therapeutics, Inc.
PLX-R18 is currently in development as a countermeasure for acute radiation syndrome and as a treatment for incomplete recovery following hematopoietic cell transplantationData from 1st and 2nd...
Pluristem Therapeutics to Host Key Opinion Leader Call on Its Acute Radiation Syndrome and Hematological Programs
September 09, 2019 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced...
Pluristem Therapeutics to Host Key Opinion Leader Call on its Acute Radiation Syndrome and Hematological Deficiencies Programs
August 21, 2019 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem and U.S. Department of Defense Present Positive Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome
July 31, 2019 08:00 ET
|
Pluristem Therapeutics, Inc.
PLX-R18 demonstrated significant increase in survival rates and recovery of the three blood lineagesData is jointly presented at the 2019 Radiation Injury Treatment Network (RITN) Workshop HAIFA,...
Pluristem Therapeutics’ CEO Issues Shareholders Update
July 24, 2019 10:45 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, July 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem Announces One-for-Ten Reverse Split of its Common Shares
July 24, 2019 02:45 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, July 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem and U.S. Department of Defense to Announce Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome at RITN
July 17, 2019 07:00 ET
|
Pluristem Therapeutics, Inc.
Data will be jointly presented at the upcoming 2019 Radiation Injury Treatment Network (RITN) Workshop on July 31st HAIFA, Israel, July 17, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc....
Pluristem Therapeutics’ CEO Issues Shareholder Letter
July 02, 2019 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, July 02, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...